Improved survival in liver transplant patients receiving prolonged-release tacrolimus-based immunosuppression in the European Liver Transplant Registry (ELTR): an extension study.

Date publication

mai 2019

Journal

Transplantation

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BACHELLIER Philippe , Pr HEYD Bruno

Tous les auteurs :
Adam R, Karam V, Cailliez V, Trunečka P, Samuel D, Tisone G, Němec P, Soubrane O, Schneeberger S, Gridelli B, Bechstein WO, Risaliti A, Line PD, Vivarelli M, Rossi M, Pirenne J, Klempnauer JL, Rummo A, Di Benedetto F, Zieniewicz K, Troisi R, Paul A, Vali T, Kollmar O, Boudjema K, Hoti E, Colledan M, Pratschke J, Lang H, Popescu I, Ericzon BG, Strupas K, De Simone P, Kochs E, Heyd B, Gugenheim J, Pinna AD, Bennet W, Kazimi M, Bachellier P, Wigmore SJ, Rasmussen A, Clavien PA, Hidalgo E, O'Grady JG, Zamboni F, Kilic M, Duvoux C,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31343568

Résumé

We compare, through the European Liver Transplant Registry, long-term liver transplantation outcomes with prolonged-release tacrolimus (PR-T) versus immediate-release-tacrolimus (IR-T)-based immunosuppression. This retrospective analysis comprises up to 8-year data collected 2008-2016, in an extension of our previously-published study.

Référence

Transplantation. 2019 May 7;: